Citius Oncology (CTOR) Proxy filing summary

Executive summary

• Annual Meeting scheduled for September 29, 2026, to elect three Class II directors and ratify the auditor for FY 2026.

• Record date for voting is August 17, 2026, with 92,981,204 shares eligible to vote.

• Proxy materials include detailed director biographies, executive compensation, and governance practices.

Voting matters and shareholder proposals

• Shareholders will vote on electing three Class II directors for terms expiring in 2029.

• Ratification of Wolf & Company, P.C. as independent auditor for FY ending September 30, 2026.

• No other shareholder proposals or nominations were submitted for this meeting.

• Procedures for future shareholder proposals and nominations are outlined, with deadlines for 2027 provided.

Board of directors and corporate governance

• Board consists of nine members divided into three classes with staggered terms.

• All directors except the CEO and Executive Vice Chairman are independent under Nasdaq standards.

• Committees include Audit and Risk, Compensation, and Nominating and Governance, all with independent members.

• Board and committees met regularly in FY 2025, with high attendance by directors.

• Code of Ethics and insider trading policy are in place; anti-hedging is discouraged but not formally prohibited.